Northern Trust
KLDO

Northern Trust’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Northern Trust’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-203,833
Closed -$336K – 4856
2022
Q1 		$336K Sell
203,833
-12,931
-6% -$23.1K ﹤0.01% 3897
2021
Q4 		$519K Sell
216,764
-5,496
-2% -$22.4K ﹤0.01% 3799
2021
Q3 		$1.21M Buy
222,260
+12,684
+6% +$78.7K ﹤0.01% 3491
2021
Q2 		$1.56M Buy
209,576
+7,841
+4% +$55.6K ﹤0.01% 3424
2021
Q1 		$1.64M Sell
201,735
-510
-0.3% -$5.56K ﹤0.01% 3354
2020
Q4 		$1.84M Buy
202,245
+501
+0.2% +$4.11K ﹤0.01% 3230
2020
Q3 		$2.23M Buy
201,744
+10,713
+6% +$74.2K ﹤0.01% 3011
2020
Q2 		$1.42M Buy
191,031
+63,714
+50% +$427K ﹤0.01% 3214
2020
Q1 		$783K Buy
127,317
+4,613
+4% +$30.1K ﹤0.01% 3317
2019
Q4 		$616K Buy
122,704
+50,563
+70% +$321K ﹤0.01% 3515
2019
Q3 		$543K Buy
72,141
+59,656
+478% +$518K ﹤0.01% 3520
2019
Q2 		$145K Buy
+12,485
New +$182K ﹤0.01% 3888

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Northern Trust's KLDO Position: Q2 2022 in Review

Northern Trust sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 203,833 shares — an estimated $336K sold.

Northern Trust first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $2.23M in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Northern Trust reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Northern Trust sold 203,833 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $336K.
  • Northern Trust first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Northern Trust's Kaleido Biosciences, Inc. Common Stock position peaked at $2.23M in Q3 2020.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Northern Trust's 13F filing for Q2 2022, filed 12 Aug 2022.